1st Speaker
Psychotropic Medications for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Review of the Evidence

Maria Reyes, M.D.

Introduction

Dr. Reyes holds B.S. degrees in psychology and biology from the University of Utah and Westminster College. She received her M.D. from the University of Utah and completed her psychiatry residency training at Mayo Clinic. She is currently completing the geriatric psychiatry fellowship and plans to join the faculty of an academic program in the Western U.S. after graduation. Her research interests include ADHD, addiction, and psychiatric manifestations of neurodegenerative disease.

Learning Objectives

1. 1. Describe the differential diagnosis of behavioral and psychological symptoms in patients with dementia.
2. 2. Recognize when and how to prescribe psychotropics in this population.
3. 3. Familiarize clinicians with the current evidence base regarding the benefits and risks associated with the use of psychotropics in patients with dementia.

2nd Speaker

Neurophysiologic Measures of Cortical Excitation and Inhibition in Pediatric Depression

Charles Lewis, M.D.

Introduction

Dr. Lewis pursued undergraduate studies in Psychology at Rice University, where he obtained a Bachelor of Arts degree in 2005.  He later attended the University of Texas Medical School at Houston, where he obtained the degree of Doctor of Medicine in 2010.  Dr. Lewis completed residency training in Psychiatry at the Mayo School of Graduate Medical Education in 2014, where he also served as Chief Resident and was a member of the residency program’s research track.  Currently in his second year of Child and Adolescent Psychiatry training, where he is a Chief Resident, Dr. Lewis will be pursuing additional clinical research training through the Clinician-Investigator Training Program at the MSGME beginning in 2016.  Dr. Lewis’ research interests focus on the neurophysiology of excitatory and inhibitory neurotransmitters, as well as brain stimulation techniques, in pediatric mood disorders and suicidality.  Under the mentorship of Dr. Paul Croarkin, Dr. Lewis has presented research findings at several national and international conferences, including the Society of Biological Psychiatry, American College of Neuropsychopharmacology, and the American Academy of Child and Adolescent Psychiatry. 

Learning Objectives

1. Review the basic neurobiology of glutamatergic and GABAergic neurotransmitter systems and evidence for their roles in pediatric depression.
2. Recognize noninvasive transcranial magnetic stimulation (TMS) techniques for measuring cortical GABAergic and glutamatergic functions.
3. Summarize currently limited findings of research on TMS-measured excitatory and inhibitory neurophysiology in pediatric depression.

Live webcast available at:  http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  MedHub will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please send an email to rstpsychgr@mayo.edu. The badge reader should continue to be utilized for Gonda and Sister Helen Hayes locations.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

Disclosure Summary
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry: Dr. Lewis has grant/research support from Mayo Clinic Foundation Department Small Grant Program and Neuronetics, Inc.
 
No relevant financial relationship(s) with industry:
Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, M.D., Patricia Maus, M.D., Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Dr. Reyes intends to discuss off-label/investigative uses of the following commercial products: citalopram, trazodone, sertraline, quetiapine, aripiprazole, risperidone, olanzapine, carbamazepine, donepezil, memantine, valproate, oxcarbazepine, galantamine, rivastigmine.

Dr. Lewis intends to discuss off-label/investigative uses of the following commercial products/devices:

Manufacturer/Provider: Neuronetics, Inc. / Products/Devices: NeuroStar (rTMS)

Manufacturer/Provider: multiple (generic medication). / Products/Devices: ketamine for treatment of depression

Questions regarding this program can be directed to Amber Pearson at Pearson.Amber@mayo.edu.